Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenqimaixintong Capsule is a Traditional Chinese Medicine (TCM) formulation developed by Guangzhou Traditional and West Medicine Integrated Hospital for the treatment and prevention of atherosclerosis. It functions through bidirectional immune regulation, specifically modulating the Toll-like receptor (TLR) signaling pathway to influence inflammatory immune markers. The drug has been evaluated in Phase 4 clinical trials in China, where its effects on carotid atherosclerosis and inflammatory markers were compared to standard atorvastatin therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenqimaixintong Capsule.